Zacks Investment Research recorded AbbVie Inc (NYSE:ABBV), bumping its target to $72.00 earlier today
- Updated: September 28, 2016
Zacks Investment Research bumped up the target of AbbVie Inc (NYSE:ABBV) to $72.00 stating a potential upside of 0.13%.
On 09/08/2016, Vetr Inc. released a statement for AbbVie Inc (NYSE:ABBV) bumped up the target price from $0.00 to $72.59 that suggested an upside of 0.12%.
Boasting a price of $63.96, AbbVie Inc (NYSE:ABBV) traded -0.79% lower on the day. With the last stock price close up 2.95% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. AbbVie Inc has recorded a 50-day average of $64.97 and a two hundred day average of $62.23. Volume of trade was down over the average, with 1,888,906 shares of ABBV changing hands under the typical 7,017,290
With a total market value of $0, AbbVie Inc has price-earnings ratio of 18.48 with a one year low of $45.45 and a one year high of $68.12 .
A total of 18 equity analysts have released a research note on ABBV. Four equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, five equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $70.22.
Brief Synopsis About AbbVie Inc (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.